Genta Appeals FDA’s Genasense “Not Approvable” Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says oncologic deserves approval after demonstrating a complete response in patients with CML.
You may also be interested in...
Genta Gets New FDA Action Date For Genasense In CLL
Firm has SPA for additional trial pending at agency, chairman said in an interview.
Genta Gets New FDA Action Date For Genasense In CLL
Firm has SPA for additional trial pending at agency, chairman said in an interview.
FDA Clears Path For Genta’s Genasense In Chronic Lymphocytic Leukemia
Agency acknowledges complete response as an appropriate primary endpoint for study; needs confirmatory evidence.